SGS is pleased to welcome into our group Quay Pharmaceuticals Limited (Quay Pharma), a UK-based provider of innovative, formulation research and development services for the global biopharmaceutical sector.
Quay Pharma is a leading innovative Formulation Research and Development Organization with a comprehensive and flexible range of services. It supports its customers through the various stages of pharmaceutical clinical development, from pre-formulation to formulation, dosage form design and optimization. Quay Pharma serves over 150 clients globally and is in the process of opening a new sizeable laboratory on the East Coast of the United States, adding a range of complementary services to Quay Pharma’s existing UK facilities.
Founded in 2002, the company has grown consistently since inception and generated revenues of circa CHF 21 million in the fiscal year ending May 31, 2021. Through the acquisition, SGS welcomes circa 200 highly skilled scientists and technicians to our Health Science group and the current management team will continue to lead the business.
This acquisition represents a meaningful step forward in SGS’s strategy of increasing the scope of services to support our customers across the Health Science supply chain. Quay Pharma will become our global Center of Excellence for Formulation, Research and Development. It adds to our comprehensive portfolio of analytical services, further reinforces our TIC leadership position and enables us to better serve the needs of our global biopharmaceutical customers.
Frankie Ng, CEO of SGS said: “This acquisition supports our strategic evolution by further aligning our global network ever more closely to TIC megatrends. Quay Pharma adds a significant level of competence to the Group and allows us to offer more comprehensive and complex, high value-added services to our customers.”
